Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia

Measurable residual disease testing in acute myeloid leukaemia

(2017) C S Hourigan et al.   LEUKEMIA

Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia

(2016) Y Zhou et al.   LEUKEMIA

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Should minimal residual disease guide therapy in AML?

(2015) Elisabeth Paietta   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML

(2015) Ivana Jeziskova et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood

(2015) Kunio Kitamura et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia

(2015) Xueyan Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia

(2015) C. Michel Zwaan et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement

(2014) M. Pigazzi et al.   HAEMATOLOGICA

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse

(2014) T Köhnke et al.   LEUKEMIA

Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia

(2014) Li Zhang et al.   PEDIATRIC BLOOD & CANCER

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

(2013) Monique Terwijn et al.   JOURNAL OF CLINICAL ONCOLOGY

Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children

(2013) D Tomizawa et al.   LEUKEMIA

Minimal residual disease in acute myeloid leukaemia

(2013) Christopher S. Hourigan et al.   Nature Reviews Clinical Oncology

Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel

(2012) U. Creutzig et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

(2012) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

(2011) Jan Krönke et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia

(2011) Emna Abdelhamid et al.   LEUKEMIA RESEARCH

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study

(2009) B. V. Balgobind et al.   BLOOD

Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia

(2008) Luca Maurillo et al.   JOURNAL OF CLINICAL ONCOLOGY